New schizophrenia drug injection shows promise in bioequivalence trial
NCT ID NCT07268430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a new paliperidone palmitate injection works the same as the standard one in 256 Chinese patients with schizophrenia. Patients received either the new or the standard injection, and researchers measured drug levels in the blood to see if they matched. The goal was to show the new version is equivalent, which could lead to more treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paliperidone palmitate injection
What this could lead to
If successful, this could show that the new injection is equivalent to the existing one, potentially offering a more affordable or accessible treatment option for schizophrenia.
What could go wrong
This is a bioequivalence study, not a test of effectiveness. It only checks if the drug levels in the blood match the reference product. The trial is completed, but results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anding Hospital Capital Medical University
Beijing, Beijing Municipality, China